TICKERNERD
Menu
DCTHDCTHHealthcare · Medical Devices

DCTH Stock Forecast: Delcath Systems, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$16
+0.70% on the day

The 5 Wall Street analysts covering Delcath Systems, Inc. hold a median 12-month price target of $22 — +38.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$552.1M
Ticker Nerd rank
96 / 100
Median analyst target
$22
Analysts covering
5
Revenue$29.1M+20.6% y/y
Operating income$2.4M
Net income$2.7M
Free cash flow$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
−7.6%
YTD
+57.5%
1Y
+42.9%
From 52W high
−8.4%
From 52W low
+94.3%
$8
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DCTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Delcath Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Value
99
Revisions
96
Accruals
77
Volatility
70
Momentum
70
Size
52
Issuance
39
Growth
36

Quality (100): The business earns solid, repeatable profits on what it owns.

Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DCTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DCTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26DCTHHigh $32Median $22Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $21Median $22High $32

The green dot is the last close — the median target sits +38.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
7 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $32
6 Aug 2026BTIGMaintainsBuy$17 → $21
26 Feb 2026BTIGMaintainsBuy—
26 Feb 2026BTIGMaintainsBuy$23 → $19
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025Stephens & Co.MaintainsOverweight—
4 Nov 2025BTIGReiteratesBuy—
21 Oct 2025Canaccord GenuityMaintainsBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
23 June 2025Stephens & Co.ReiteratesOverweight—
23 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025HC Wainwright & Co.MaintainsBuy—
17 Jan 2025Craig-HallumMaintainsBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024Canaccord GenuityMaintainsBuy$21
18 Oct 2024HC Wainwright & Co.ReiteratesBuy$22
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024Stephens & Co.ReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DCTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Delcath Systems, Inc. returned +42.9% against +17.5% for the S&P 500, dividends included.

DCTH vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26DCTHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DCTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Delcath Systems, Inc. (DCTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1591.0×

Cheaper than 1% of US stocks

Price / sales
5.8×

Cheaper than 22% of US stocks

Price / book
4.5×

Cheaper than 23% of US stocks

EV / EBITDA
−315.2×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
20.6%

Higher than 70% of US stocks

Earnings growth (YoY)
−1.1%

Higher than 35% of US stocks

Gross margin
89.8%

Higher than 96% of US stocks

Operating margin
8.2%

Higher than 61% of US stocks

Net margin
0.6%

Higher than 48% of US stocks

Returns & dividend
Return on equity
0.5%

Higher than 45% of US stocks

Return on assets
−0.9%

Higher than 40% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Delcath Systems, Inc. (DCTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Delcath Systems, Inc. has a market value of $552.1M and an enterprise value of $458.6M.

  • Revenue in the twelve months to 30 June 2026: $95.4M. The latest quarter grew 20.6% year on year.

  • Net income over the same four quarters: $532K, a 0.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.01.

  • Free cash flow in the twelve months to 30 June 2026: $17.5M.

  • Shares outstanding: 34.6M.

  • Trailing P/E: 1591.0×; forward P/E: 353.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Delcath Systems, Inc. employs 156 people — $612K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

DCTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
DCTHDelcath Systems, Inc.$552.1M
96
KIDSOrthoPediatrics Corp.$553.2M
65
CTKBCytek Biosciences, Inc.$595.3M
64
TCMDTactile Systems Technology, Inc.$505.3M
97
CERSCerus Corp.$478.3M
91
NPCENeuroPace, Inc.$472.7M
92
SSIISS Innovations International, Inc.$640.9M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Delcath Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DCTH news & analysis

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 11 Sept 2026neutral

Delcath Systems announced that it granted Restricted Stock Units to four newly hired employees as material inducements under Nasdaq Listing Rule 5635(c)(4), with the grants totaling 34,000 RSUs. The equity awards were previously approved by the Company's Compensation Committee and relate to individuals whose employment commenced in July or August 2026.

Why it matters — This discloses new equity compensation tied to recent hires, which a Delcath watcher would consider relevant to share dilution and employee recruitment incentives.

Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH

Zacks Investment Research · 8 Sept 2026positive

Zacks screened VLO, PBF, FET and DCTH as low-beta picks as market volatility rises, citing growth drivers in refining, energy equipment and liver-cancer treatment for DCTH.

Why it matters — DCTH watchers would care because the article highlights the company as a lower-volatility option supported by its liver-cancer growth driver during periods of market turbulence.

5 Stocks With Recent Price Strength Buoyed by a Strong August

Zacks Investment Research · 4 Sept 2026positive

Delcath Systems (DCTH) was named among five stocks showing strong recent price momentum after a strong August, with the strength backed by improving earnings expectations, according to Zacks Investment Research.

Why it matters — DCTH watchers would note that the stock's price strength is supported by improving earnings expectations, a positive fundamental signal for the company.

Delcath Systems to Participate in Upcoming Investor Conferences

Business Wire · 31 Aug 2026neutral

Delcath Systems announced that management will attend the Wells Fargo Healthcare Conference on September 10, 2026, in Boston, MA, and the H.C. Wainwright 27th Annual Global Investment Conference on September 15, 2026, in New York, NY. The company focuses on interventional oncology treatments for primary and metastatic cancers of the liver.

Why it matters — Participation in these investor conferences gives DCTH watchers an opportunity to hear management present the company's status and strategy to the investment community.

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 28 Aug 2026positive

Zacks Investment Research published a piece examining whether Delcath Systems, Inc. (DCTH) could serve as a top pick for momentum investors, based on the company's stock momentum characteristics.

Why it matters — DCTH watchers would care because the article evaluates the company's appeal to momentum-driven investors, which could influence how its stock is viewed in the market.

FAQ

Frequently asked questions about DCTH stock

What is the DCTH stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Delcath Systems, Inc. have a median 12-month price target of $22, with estimates ranging from $21 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DCTH stock a buy right now?

Of the 5 analysts covering Delcath Systems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Delcath Systems, Inc. 96 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DCTH?

As at 12 Sept 2026, Delcath Systems, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will DCTH stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +38.3% from the last close, and Ticker Nerd's factor model ranks Delcath Systems, Inc. 96 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DCTH stock forecast for 2030?

No analyst covering Delcath Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $32 over the next 12 months.

How has DCTH stock performed over the past year?

Delcath Systems, Inc. returned +42.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Delcath Systems, Inc. do?

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

What is the latest news on DCTH?

The most recent item we track (Business Wire, 11 Sept 2026): "Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Delcath Systems announced that it granted Restricted Stock Units to four newly hired employees as material inducements under Nasdaq Listing Rule 5635(c)(4), with the grants totaling 34,000 RSUs. The equity awards were previously approved by the Company's Compensation Committee and relate to individuals whose employment commenced in July or August 2026.

Company

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects. Its current product portfolio includes HEPZATO KIT in the United States and CHEMOSAT in Europe, both used in hepatic delivery procedures for liver cancer care. Delcath Systems serves specialized oncology centers and medical professionals that treat patients with liver tumors, positioning its technologies within the broader medical device and specialty pharmaceutical markets. Headquartered in Queensbury, New York, Delcath Systems plays a focused role in targeted cancer treatment by combining pharmaceutical and device-based approaches for liver-directed therapy.

CEO Mr. Gerard J. Michel MBA, MS · 156 employees · United States · https://www.delcath.com